The global corona pandemic requires effective vaccines to achieve herd immunity. In the study presented here, an inhalable chitosan-based nanovaccine containing the viral spike protein (S) was developed to specifically induce immunity at the mucosal sites of the respiratory tract.

Chronic, painful diseases such as endometriosis can lead to a severe reduction in the quality of life of those affected. Drug delivery systems, such as chitosan-containing hydrogels, could enable efficient pain management with prolonged and targeted drug release. Therefore, in the study presented here, hydrogels made of chitosan and the vanillin derivative 2-hydroxy-5-nitrobenzaldehyde were investigated as a drug delivery system for diclofenac sodium salt.